Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Moderna Rises After Flu Shot Beats Sanofi, GSK VaccinesModerna (MRNA) shares rose on Wednesday after the firm said that its experimental flu shot beat widely used vaccinations from Sanofi and GSK.
By: Medical Infralytix Pvt Ltd According to Moderna, the experimental flu vaccination accomplished the aim of a final-phase trial. One analyst, however, dubbed the vaccine "a commercial nonstarter," The announcement comes only days after the FDA approved enhanced Covid vaccines from Moderna and Pfizer (PFE) alongside partner BioNTech (BNTX). Meanwhile, the FDA is considering whether to approve Moderna's respiratory syncytial virus vaccine. Obtaining all three approvals, according to Moderna Chief Financial Officer Jamey Mock, opens the door to a plethora of possible vaccination combinations. Meanwhile, the business is collaborating with Merck (MRK) on a Phase 3 trial of lung cancer patients. Moderna anticipates launching 15 new items during the next five years. It anticipates an increase in yearly sales of cancer, rare and latent disease medications of $10 billion to $15 billion by 2028, and respiratory treatments of $8 billion to $15 billion in 2027. Catch up-to-date press release and more at Medical Infralytix Pvt Ltd services, do visit our website at https://meditherma.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|